Genomic profiling maps loss of heterozygosity and defines the timing and stage dependence of epigenetic and genetic events in Wilms' tumors

Molecular Cancer Research

Volumn 3, Issue 9, 2005, Pages 493-502

  Yuan, Eric ^a   Li, Chi Ming ^a   Yamashiro, Darrell J ^a   Kandel, Jessica ^a   Thaker, Harshwardhan ^a   Murty, Vundavalli V ^a   Tycko, Benjamin ^a  

^a NewYork Presbyterian Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SOMATOMEDIN B;

5' UNTRANSLATED REGION; ADVANCED CANCER; ANIRIDIA; ARTICLE; CANCER STAGING; CARCINOGENESIS; CHROMOSOME 11P; CHROMOSOME 11Q; CHROMOSOME 14Q; CHROMOSOME 16Q; CHROMOSOME 17P; CHROMOSOME 1P; CHROMOSOME 4Q; CHROMOSOME 7P; CHROMOSOME LOSS; CHROMOSOME MOSAICISM; CONTROLLED STUDY; DENYS DRASH SYNDROME; DNA FINGERPRINTING; DNA METHYLATION; EARLY CANCER; EPIGENETICS; GENE MAPPING; GENOME ANALYSIS; GENOME IMPRINTING; HETEROZYGOSITY LOSS; HUMAN; HUMAN TISSUE; KARYOTYPE; NEPHROBLASTOMA; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

BLOTTING, NORTHERN; BLOTTING, SOUTHERN; CHROMOSOMES, HUMAN; DNA FINGERPRINTING; DNA METHYLATION; EPIGENESIS, GENETIC; GENOME; HUMANS; INSULIN-LIKE GROWTH FACTOR II; KIDNEY NEOPLASMS; LOSS OF HETEROZYGOSITY; MICROARRAY ANALYSIS; NEOPLASM RECURRENCE, LOCAL; POLYMORPHISM, SINGLE NUCLEOTIDE; RNA, UNTRANSLATED; TUMOR CELLS, CULTURED; WILMS TUMOR; WT1 PROTEINS;

EID: 25444471062     PISSN: 15417786     EISSN: None     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-05-0082     Document Type: Article

References (49)

1. Knudson AG, Jr., Strong LC. Mutation and cancer; a model for Wilms' tumor of the kidney. J Natl Cancer Inst 1972:48:313-24.
2. Riccardi VM, Sujansky E, Smith AC, Francke U. Chromosomal imbalance in the Aniridia-Wilms' tumor association: lip interstitial deletion. Pediatrics 1978; 61:604-10.
3. Francke U, Holmes LB, Atkins L, Riccardi VM. Aniridia-Wilms' tumor association: evidence for specific deletion of 11p13. Cytogenet Cell Genet 1979; 24:185-92.
4. Kaneko Y, Egues MC, Rowley JD. Interstitial deletion of short arm of chromosome 11 limited to Wilms' tumor cells in a patient without aniridia. Cancer Res 1981;41:4577-8.
5. Call KM, Glaser T, Ito CY, et al. Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilms' tumor locus. Cell 1990: 60:509-20.
6. Gessler M, Poustka A, Cavenee W, Neve RL, Orkin SH, Bruns GA. Homozygous deletion in Wilms tumours of a zinc-finger gene identified by chromosome jumping. Nature 1990;343:774-8.
7. Haber DA, Buckler AJ, Glaser T, et al. An internal deletion within an 11p13 zinc finger gene contributes to the development of Wilms' tumor. Celt 1990;61: 1257-69.
8. Gessler M, Konig A. Arden K, et al. Infrequent mutation of the WTI gene in 77 Wilms' Tumors. Hum Mutat 1994;3:212-22.
9. Li CM, Kim CE, Margolin AA, et al. CTNNB1 mutations and overexpression of Wnt/β-catenin target genes in WT1-mutant Wilms' tumors. Am J Pathol 2004; 165:1943-53.
10. Little M, Wells C. A clinical overview of WT1 gene mutations. Hum Mutat 1997;9:209-25.
11. Feinberg AP, Tycko B. The history of cancer epigenetics. Nat Rev Cancer 2004;4:143-53.
12. Bliek J, Gicquel C, Maas S, Gaston V, Le Bouc Y, Mannens M. Epigenotyping as a tool for the prediction of tumor risk and tumor type in patients with Beckwith-Wiedemann syndrome (BWS). J Pediatr 2004;145:796-9.
13. Sparago A, Cerrato F, Vernucci M. Ferrero GB, Silengo MC, Riccio A. Microdeletions in the human H19 DMR result in loss of IGF2 imprinting and Beckwith-Wiedemann syndrome. Nat Genet 2004;36:958-60.
14. Yeh A, Wei M, Golub SB, Yamashiro DJ, Murty VV, Tycko B. Chromosome arm 16q in Wilms tumors: unbalanced chromosomal translocations, loss of heterozygosity. and assessment of the CTCF gene. Genes Chromosomes Cancer 2002;35:156-63.
15. Grundy PE, Telzerow PE, Breslow N, Moksness J, Huff V, Paterson MC. Loss of heterozygosity for chromosomes 16q and 1p in Wilms' tumors predicts an adverse outcome. Cancer Res 1994;54:2331-3.
16. Sous V, Pritchard J, Cowell JK. Cytogenetic changes in Wilms' tumors. Cancer Genet Cytogenet 1988;34:223-34.
17. Sandoval C, Stringel G, Ozkaynak MF, Tugal O, Jayabose S. Isochromosome 7q and Wilms tumor. Cancer Genet Cytogenet 1998;104:61-5.
18. Rubin BP, Pins MR, Nielsen GP. et al. Isochromosome 7q in adult Wilms' tumors: diagnostic and pathogenetic implications. Am J Surg Pathol 2000; 24:1663-9.
19. Powlesland RM, Charles AK. Malik KT, et al. Loss of heterozygosity at 7p in Wilms' tumour development. Br J Cancer 2000;82:323-9.
20. Peier AM, Meloni AM, Erling MA, Sandberg AA. Involvement of chromosome 7 in Wilms tumor. Cancer Genet Cytogenet 1995;79:92-4.
21. Fletcher JA. Renshaw AA. Isochromosome 7q in adult Wilms' tumor. Cancer Genet Cytogenet 1996;86:168-9.
22. Peres EM, Savasan S, Cushing B, Abella S, Mohamed AN. Chromosome analyses of 16 cases of Wilms tumor: different pattern in unfavorable histology. Cancer Genet Cytogenet 2004;148:66-70.
23. Dao D, Walsh CP, Yuan L, et al. Multipoint analysis of human chromosome 11p15/mouse distal chromosome 7: inclusion of H19/IGF2 in the minimal WT2 region, gene specificity of H19 silencing in Wilms' tumorigenesis and methylation hyper-dependence of H19 imprinting. Hum Mol Genet 1999;8:1337-52.
24. Coppes MJ, Bonetta L, Huang A, et al. Loss of heterozygosity mapping in Wilms tumor indicates the involvement of three distinct regions and a limited role for nondisjunction or mitotic recombination. Genes Chromosomes Cancer 1992; 5:326-34.
25. Mannens M, Devilee P, Blick J, et al. Loss of heterozygosity in Wilms' tumors, studied for six putative tumor suppressor regions, is limited to chromosome 11. Cancer Res 1990;50:3279-83.
26. Slater RM, de Kraker J, Voûte PA, Delemarre JF. A cytogenetic study of Wilms' tumor. Cancer Genet Cytogenet 1985;14:95-109.
27. Sheng WW, Soukup S, Bove K, Gorwals B, Lampkin B. Chromosome analysis of 31 Wilms' tumors. Cancer Res 1990;50:2786-93.
28. Kaneko Y, Homma C. Maseki N, Sakurai M, Hata J. Correlation of chromosome abnormalities with histological and clinical features in Wilms' and other childhood renal tumors. Cancer Res 1991;51:5937-42.
29. Hoglund M, Gisselsson D, Hansen GB, Mitelman F. Wilms tumors develop through two distinct karyotypic pathways. Cancer Genet Cytogenet 2004;150:9-15.
30. Hino S, Kishida S, Michiue T, et al. Inhibition of the Wnt signaling pathway by Idax, a novel Dv1-binding protein. Mol Cell Biol 2001;21:330-42.
31. London TB, Lee HJ, Shao Y, Zheng J. Interaction between the internal motif KTXXXI of Idax and mDv1 PDZ domain. Biochem Biophys Res Commun 2004; 322:326-32.
32. Michiue T, Fukui A, Yukita A, et al. XIdax, an inhibitor of the canonical Wnt pathway, is required for anterior neural structure formation in Xenopus. Dev Dyn 2004;230:79-90.
33. Weirich A, Ludwig R, Graf N, et al. Survival in nephroblastoma treated according to the trial and study SIOP-9/GPOH with respect to relapse and morbidity. Ann Oncol 2004;15:808-20.
34. Shamberger RC, Guthrie KA, Ritchey ML, et al. Surgery-related factors and local recurrence of Wilms tumor in National Wilms Tumor Study 4. Ann Surg 1999;229:292-7.
35. Bardeesy N, Falkoff D, Petruzzi MJ, et al. Anaplastic Wilms' tumour, a subtype displaying poor prognosis, harbours p53 gene mutations. Nat Genet 1994; 7:91-7.
36. Moulton T, Crenshaw T, Hao Y, et al. Epigenetic lesions at the HI9 locus in Wilms' tumour patients. Nat Genet 1994;7:440-7.
37. Maiti S, Alam R, Amos CI, Huff V. Frequent association of β-catenin and WTl mutations in Wilms tumors. Cancer Res 2000;60:6288-92.
38. Ravenel JD, Broman KW, Perlman EJ. et al. Loss of imprinting of insulin-like growth factor-II (IGF2) gene in distinguishing specific biologic subtypes of Wilms tumor. J Natl Cancer Inst 2001;93:1698-703.
39. Ruteshouser EC, Hendrickson BW, Colella S, Krahe R, Pinto L, Huff V. Genome-wide loss of heterozygosity analysis of WT1-wild-type and WT1-mutant Wilms tumors. Genes Chromosomes Cancer 2005;43:172-80.
40. 1, in the embryonic kidney. J Cell Biol 2001;154:447-58.
41. Huang JT, Lee V. Identification and characterization of a novel human nephronectin gene in silico. Int J Mol Med 2005;15:7l9-24.
42. 8 expression in the developing kidney. Proc Natl Acad Sci U S A 2002; 99:8090-5.
43. Hartner A, Haas C, Amann K, Sterzel RB. Aspects of the renal phenotype of adult ag integrin-deficient mice. Nephrol Dial Transplant 2002;17 Suppl 9: 71-2.
44. 1 is critically important for epithelial-mesenchymal interactions during kidney morphogenesis. Cell 1997;88:603-13.
45. Okamoto K, Morison IM, Taniguchi T, Reeve AE. Epigenetic changes at the insulin-like growth factor II/HI9 locus in developing kidney is an early event in Wilms tumorigenesis. Proc Natl Acad Sci U S A 1997;94:5367-71.
46. DeBaun MR, Niemitz EL, McNeil DE, Brandenburg SA, Lee MP, Feinberg AP. Epigenetic alterations of H19 and LtT1 distinguish patients with Beckwith-Wiedemann syndrome with cancer and birth defects. Am J Hum Genet 2002; 70:604-11.
47. Engel JR, Smallwood A, Harper A, et al. Epigenotype-phenotype correlations in Beckwith-Wiedemann syndrome. J Med Genet 2000;37:921-6.
48. Mummert SK, Lobanenkov VA, Feinberg AP. Association of chromosome arm 16q loss with loss of imprinting of insulin-like growth factor-II in Wilms tumor. Genes Chromosomes Cancer 2005;43:155-61.
49. Liu WM, Di X, Yang G, et al. Algorithms for large-scale genotyping microarrays. Bioinformatics 2003;19:2397-403.